EU regulators halt CBD supplement approval over safety data gaps

The European Food Safety Authority (EFSA) has raised significant concerns about the safety approval of isolated cannabidiol (CBD) as a novel food ingredient in the European Union. The proposed CBD isolate—a white powder containing ≥97% pure CBD with trace levels of other cannabinoids—was intended for use in food supplements at 21 mg/day for healthy adults, excluding pregnant and nursing women. However, after reviewing the manufacturer's safety data, the EFSA Panel identified critical gaps in the evidence.

The key issue centers on uncertainty about product formulation and the potential presence of nanoparticles in the final food products. The crystallization and processing methods used to create the isolate raise questions about whether small particles could form during production, and whether the safety testing adequately addressed these possibilities. Without clarity on formulation details, the testing strategies used to evaluate absorption, metabolism, and toxicity cannot be confirmed as sufficient to protect consumer safety. The Panel concluded that safety cannot be established under the proposed conditions of use, effectively blocking approval despite CBD being a purified, well-studied cannabinoid.

This decision highlights how regulatory frameworks around novel foods require not just evidence that a substance is safe, but also comprehensive documentation of exactly how it will be manufactured and delivered to consumers. For the CBD industry, approval will require either reformulation clarity, additional safety testing, or both—making this a watershed moment in how cannabinoid-derived ingredients are regulated in food systems across Europe.